XML 43 R31.htm IDEA: XBRL DOCUMENT v3.7.0.1
Collaborative Research and Development Agreements - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Nov. 30, 2016
Mar. 31, 2017
Dec. 31, 2016
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Dec. 31, 2016
Dec. 31, 2014
Dec. 31, 2012
Dec. 31, 2011
Deferred Revenue Arrangement [Line Items]                    
Liability related to unused development funding     $ 11,192,000   $ 7,184,000   $ 11,192,000      
Maximum                    
Deferred Revenue Arrangement [Line Items]                    
Additional revenue recognized         100,000,000          
Astra Zeneca                    
Deferred Revenue Arrangement [Line Items]                    
Collaboration Revenue               $ 5,400,000   $ 3,000,000
Payments received for development work               $ 8,000,000 $ 6,000,000 $ 3,000,000
Additional collaboration revenue             800,000      
Milestone payments earned $ 7,200,000                  
Unused development funding advanced by AstraZeneca $ 7,400,000                  
Milestone revenue recognition     7,200,000 $ 34,000   $ 104,000        
Unused development funding paid   $ 200,000                
Liability related to unused development funding         0          
Deferred revenue     $ 0   $ 0   $ 0